2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Microbiome, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Diseases, Immunology, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Study Population, Human, Adult, Elderly
PAPER

3913 An expanded indel taxonomy broadens the repertoire of mutational processes shaping the multiple myeloma genome

Marios Papadimitriou, MD, Abhishek Pandey, MD, MS2, Alexandra M Poos, PhD3, Michael Durante, MD, PhD4, Chrissy Baker, MSc5, Enze Liu, PhD6, Sreejeta Mondal7, Tomas Jelinek Sr, MD8, Bachisio Ziccheddu9, Francesco Maura, MD10, Florence Magrangeas11, Stéphane Minvielle Sr12, Elias K. Mai, MD13, Katja Weisel, MD14, Roland Fenk, MD15, Marc-Steffen Steffen Raab, MD16, Hartmut Goldschmidt, MD17, Ola Landgren, MD, PhD18, Eric Letouze, PhD19, Brian Walker, PhD20, Niels Weinhold, PhD21, Benjamin Diamond, MD22
1 University of Miami, Miami, Florida, United States
2 University of Miami, Miami, Florida, United States
3 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
4 University of Miami, Miami, Florida, United States
5 University of Miami, Miami, Florida, United States
6 University of Miami, Miami, Florida, United States
7 University of Miami, Miami, Florida, United States
8 University Hospital Ostrava and Faculty of Medicine, Ostrava, Czech Republic
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Center for Cancer Research Nantes-Angers, Nantes, France
12 Center for Cancer Research Nantes-Angers, Nantes, France
13 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
14 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
15 University-Hospital Duesseldorf, Duesseldorf, Germany
16 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
17 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
18 University of Miami, Miami, Florida, United States
19 Center for Cancer Research Nantes-Angers, Nantes, France
20 University of Miami, Miami, Florida, United States
21 Heidelberg University Hospital and Medical Faculty Heidelberg, Heidelberg, Germany
22 University of Miami, Miami, Florida, United States

Introduction

Insertion-deletions (InDels) are a substantial component of the genomic landscape of multiple myeloma (MM), yet the mutational processes responsible remain poorly characterized compared to other lesions such as single base substitutions (SBS). Recently, an expanded 89-feature InDel taxonomy was developed to improve resolution of overlapping mutational processes (Koh et al., Nat Gen, 2025). We applied this framework to characterize the InDel landscape of MM.

Methods
We included whole-genome sequencing (WGS) from 461 MM patients [318 newly diagnosed MM (NDMM) and 143 relapsed/refractory MM (RRMM)] with a median tumor and germline coverage of 88× and 47×, respectively. De novo InDel signature extraction (Koh et al., Nat Gen, 2025),  pairwise deconvolution, and consensus fitting (modified mmsig; Diamond et al., Blood Cancer Discovery, 2025) were sequentially deployed.

Results
The median InDel burden was 436 (range, 88–8,257). Four consensus signatures were extracted that deconvoluted into seven reference InDel processes (InD1, InD2a, InD4a, InD7, InD9a, InD11, and InD29). InD1 and InD2a are associated with replication slippage and InD4a corresponds to TOP1-mediated mutagenesis.

InD9a strongly correlated with APOBEC SBS signatures (SBS2/SBS13; r=0.41, p<0.01) and the association was strengthened with the observation that APOBEC-mediated kataegis sites were enriched for this InDel signature. Clinically, hyper-APOBEC mutagenesis is known to confer poor prognosis. In line, tumors with SBS2/SBS13 proportions >11% (hyper-APOBEC) demonstrated inferior progression-free survival (PFS) in NDMM although SBS2/SBS13 failed to stratify outcome within the remaining patients. However, median InD9a exposure separated non-hyper-APOBEC patients into groups with distinct outcomes (PFS; p=0.008), indicating APOBEC-associated InDels provide additional prognostic resolution.

InD29, similar to InD8 [cosim=0.76; non-homologous end joining (NHEJ)], showed enrichment of deletions with microhomology at breakpoint junctions, consistent with NHEJ repair. InD29 exposure correlated with both absolute SV burden (p=0.02) as well as the genome-wide dispersion of SV breakpoints (i.e., bins; p<0.001). Restricting the analysis to InDels located within ±50 bp of SV breakpoints generated a profile closely matching InD8 (cosim=0.92), further linking these InDels to NHEJ-mediated SV repair. InD29 was detectable in NDMM; however, its contribution was higher in RRMM and significantly enriched following melphalan exposure (p=0.01). These findings suggest endogenous double-strand break repair generates InD8/InD29 throughout MM evolution, while melphalan-induced DNA damage further increases this burden in RRMM.

To identify recurrent regions of InDel activity, we performed genome-wide hotspot analysis using piecewise constant fitting (PCF) and found immunglobulin loci and TXNDC5, unexpectedly, to be highly enriched. We identified 82 TXNDC5 InDels, mainly in the 3'UTR and adjacent introns, comprised of 66.7% InD8 and 33.3% InD4a, consistent with DNA double-strand breaks and TOP1-associated mutagenesis. This reflects the high transcriptional activity and importance of TXNDC5 in MM. TargetScan analysis identified 5 InDels in predicted miR-129-5p binding sites within the TXNDC5 gene locus, suggesting some InDels influence post-transcriptional regulation.

Finally, a single hypermutated case (~8000 InDels) was dominated by InD7, which is linked to mismatch repair deficiency (MMRd). An MMRd-calling tool, PRRDetect, confirmed MMRd. While the tumor had somatic loss of heterozygosity of MSH2/MSH6, a pathogenic germline MMRd variant was not observed. We therefore queried two cases from the MIDAS cohort with known MSH2 somatic and germline variants, which demonstrated a similar InD7-dominant mutational profile, supporting InD7 as a robust marker of MMRd phenotype, even in absence of obvious germline variants.

Conclusions
Various mutational processes shape the genome of MM. This InDel framework validates APOBEC-associated InDel mutagenesis at kataegis sites and suggests additional prognostic relevance of APOBEC InDels. Simultaneously we identified InD29 as an NHEJ-associated mutational process linked to structural variant repair and uncovered a recurrent non-coding hotspot with suspected regulatory significance, as well as a rare MMRd phenotype. Collectively, these findings establish InDel signatures as complementary genomic markers of clinical significance.
Marios Papadimitriou, MD: No relevant conflicts of interest to declare.